PREMCHAND GODHA

Godha trained as a chartered accountant, not a chemist. He joined Ipca Laboratories in the 1970s when it was a modest pharmaceutical company.

Over the following decades he climbed to the top and became its controlling shareholder. His big idea was unglamorous but powerful.

Instead of buying the raw chemicals that go into drugs, Ipca would make its own. That meant building factories for active pharmaceutical ingredients, the core stuff inside every pill.

It made Ipca slower to scale but far more in control of its costs and quality. He pushed the company deep into anti-malarials, the drugs that fight a disease that mostly hits poor countries with thin margins.

Today Ipca is one of the largest makers of those ingredients on earth, and Godha's stake in it made him a billionaire.

Ipca Laboratories is the whole story. It does two things at once.

It makes active pharmaceutical ingredients, the chemical building blocks of medicine, and it makes the finished pills. That backward integration is rare and it is Godha's signature move.

Ipca is a world leader in anti-malarial drugs like hydroxychloroquine and chloroquine. It also makes medicines for pain, heart conditions, and rheumatoid arthritis.

The company sells into more than 100 countries and supplies other drug makers with raw ingredients they cannot make as cheaply themselves.

Godha does not think like a stock picker. He thinks like a factory owner.

His version of investing is plowing money back into plants, chemistry, and control of his own supply chain. The logic is simple.

If you make your own raw materials, nobody can squeeze you on price or cut off your supply. It is a slower, heavier way to build a company.

It also means margins and quality stay in your hands. In plain English, he bets on owning the whole pipe instead of renting pieces of it.

Building Ipca into a global anti-malaria leader. Godha bet on a disease that most drug giants ignored because the patients are poor and the margins are thin.

By making his own active ingredients, he produced anti-malarial drugs at a scale and price others could not match. When global demand for hydroxychloroquine spiked, Ipca was already one of the biggest suppliers in the world.

The boring, decades-long bet on backward integration is what made the fortune.

The US regulatory wall. Between 2014 and 2015 the US Food and Drug Administration flagged serious problems at Ipca's manufacturing plants and restricted exports to the American market.

For a company whose whole pitch is quality and self-made ingredients, that stung. The stock took a hit and the US business, one of the most lucrative markets in pharma, was frozen for years.

It was a hard reminder that in drug making, a regulator's signature matters as much as the chemistry.

Godha's philosophy is control and patience. Own your raw materials.

Make your own ingredients. Do not depend on anyone you do not have to.

He believes margins are protected at the factory, not in the spreadsheet. He also believes a drug company's only real asset is trust, which is why a quality slip is so costly.

His approach is built for the long haul, not the quarter. Build the capability first, and the profits follow.

Godha keeps his family life private and runs Ipca as a closely held family-influenced business out of Mumbai. The Godha family holds a controlling stake in the company.

He is known among Indian business circles as understated and hands-on, far more comfortable inside a plant than in front of a camera. Public details about his personal life are deliberately sparse.

Godha qualified as a chartered accountant, India's equivalent of a CPA. He is not a scientist by training, which makes what he built even more striking.

He learned the drug business from the inside, by running it, rather than from a lab bench. The finance background shaped his instinct for control and cost.

As an Amazon Associate, Netfigo earns from qualifying purchases. Book links above may be affiliate links.